Korea Health Industry Development Institute Holds 'Vaccine Industry Collaboration Workshop'

The Korea Health Industry Development Institute announced on the 22nd that it will hold the ‘Vaccine Industry Cooperation Workshop,’ where vaccine and vaccine raw material industry companies gather in one place, on the 23rd at the Nine Tree Premier Locaus Hotel in Yongsan-gu, Seoul.

The Ministry of Health and Welfare and the Korea Health Industry Development Institute have been operating various policy projects centered on the Vaccine Industry Council to stabilize the vaccine supply chain after the COVID-19 pandemic, including R&D support, localization support for vaccine raw materials, and provision of industry information.

As part of this, the event consists of three sessions: ▲Introduction of newly joined companies in the Vaccine Industry Council ▲Introduction of domestic and international vaccine R&D support projects ▲Success stories of innovation by domestic vaccine raw material companies. It is designed as a platform for information exchange about the vaccine industry and collaboration among companies.

In the first session, 10 companies newly joined to the Vaccine Industry Council for the two years 2023?2024 will be introduced to share the current status of the council’s operations. These companies are ▲Neuracle Genetics ▲Dr. Noah Biotech ▲Lemonex ▲Medimap Bio ▲Medispan ▲CellSafe ▲Amolife Science ▲NA Vaccine Research Institute ▲Clips BNC ▲Forcevax.

The second session will feature presentations on the following topics: ▲Infectious disease R&D support and access by the Research Investment for Global Health Technology (RIGHT) Foundation to promote global health equity (RIGHT Foundation) ▲The 100-day mission and R&D strategy of the Coalition for Epidemic Preparedness Innovations (CEPI) ▲Pandemic preparedness and response vaccine development strategies in the post-COVID-19 era (Korean-style ARPA-H) ▲Introduction of investment directions of the K-Bio Vaccine Fund (Yuanta Investment). Through explanations of projects by key institutions supporting vaccine development not only in Korea but worldwide, various ways for our vaccine companies to secure R&D funding will be explored.

The third session will introduce success stories of outstanding vaccine raw material companies. Lemonex, which possesses messenger ribonucleic acid (mRNA) platform technology, will share its collaboration experience with CEPI. Excel Therapeutics, a company developing advanced media, and Curiox, which has cell analysis process technology, will share their overseas market entry strategies and success experiences.

Kim Yong-woo, head of the Pharmaceutical and Bio Industry Division at the Korea Health Industry Development Institute, said, “Considering that many vaccine and raw material companies have been struggling to secure research funds after the pandemic, we prepared this workshop to broadly provide R&D projects and market expansion strategies that our companies can receive support for from a global perspective. We hope that our companies will gain valuable information to overcome difficult times and that close communication will help them grow further.”